Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Shuichi Ota, MD PhD, Toshihiro Matsukawa, MD PhD, Satoshi Yamamoto, MD, Shinichi Ito, MD, Motohiro Shindo, MD, Kazuya Sato, MD PhD, Takeshi Kondo, MD PhD, Tohru Takahashi, MD, Tsutomu Sato, MD PhD, Yasutaka Kakinoki, MD PhD, Hajime Kobayashi, MD, Mitsutoshi Kurosawa, MD PhD

Blood (2016) 128 (22): 1898.

https://doi.org/10.1182/blood.V128.22.1898.1898

Published: 2016

Journal Articles

Risk Factor Analysis Of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndromes: A Multicenter Study

Hirozumi Sano, M.D., Ryoji Kobayashi, MD., PhD, Junji Tanaka, MD, PhD, Satoshi Hashino, MD, PhD, Shuichi Ota, MD, PhD, Yoshihiro Torimoto, MD, PhD, Yasutaka Kakinoki, MD, PhD, Satoshi Yamamoto, MD, PhD, Mitsutoshi Kurosawa, MD, PhD, Naoki Hatakeyama, MD, Yoshihito Haseyama, Hajime Sakai, Kazuya Sato, MD, PhD, Takashi Fukuhara, MD., PhD

Blood (2013) 122 (21): 1778.

https://doi.org/10.1182/blood.V122.21.1778.1778

Published: 2013

Journal Articles

Role of Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia in an HTLV-1 Non-Endemic Area of Japan.

Akio Shigematsu, MD, PhD, Junji Tanaka, MD, PhD, Naoki Kobayashi, MD, PhD, Hiroshi Yasui, MD, PhD, Motohiro Shindo, MD, PhD, Yasutaka Kakinoki, MD, PhD, Kakinoki Yasutaka, MD, PhD, Satoshi Iyama, MD, PhD, Kuroda HIroyuki, MD, PhD, Tsutsumi Yutaka, MD.PhD, Satoshi Hashino, MD, PhD, Masahiro Imamura, MD, PhD, Takanori Teshima, MD, PhD

Blood (2012) 120 (21): 3089.

https://doi.org/10.1182/blood.V120.21.3089.3089

Published: 2012

Journal Articles

Clinical Efficacy and Cost Benefit of Low-Dose Granulocyte Colony-Stimulating Factor after Standard Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.

Satoshi Hashino, MD, PhD, Masanobu Morioka, MD, PhD, Tatsuro Irie, MD, PhD, Noriyuki Shiroshita, MD, PhD, Tsugumichi Kawamura, MD, PhD, Sachiko Suzuki, MD, PhD, Hiroshi Iwasaki, MD, PhD, Shintaro Umehara, MD, PhD, Yasutaka Kakinoki, MD, PhD, Mitsutoshi Kurosawa, MD, PhD, Kaoru Kahata, MD, PhD, Koh Izumiyama, MD, PhD, Hajime Kobayashi, MD, Masahiro Onozawa, MD, Mutsumi Takahata, MD, Fumie Fujisawa, MD, Takeshi Kondo, MD, PhD, Masahiro Asaka, MD, PhD

Blood (2006) 108 (11): 4671.

https://doi.org/10.1182/blood.V108.11.4671.4671

Published: 2006

Journal Articles

Clinical Trial of Rituximab Synchronized with Granulocyte Colony-Stimulating Factor in Standard CHOP Chemotherapy for Previously Untreated Patients with Follicular or Diffuse Large B-Cell Lymphomas.

Yasutaka Kakinoki, MD, PhD, Yasushi Yamamoto, MD, Sachiko Suzuki, MD, Takashi Hukuhara, MD, PhD, Junji Tanaka, MD, PhD, Masahiro Imamura, MD, PhD

Blood (2004) 104 (11): 4579.

https://doi.org/10.1182/blood.V104.11.4579.4579

Published: 2004

NARROW

Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Risk Factor Analysis Of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndromes: A Multicenter Study

Role of Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia in an HTLV-1 Non-Endemic Area of Japan.

Clinical Efficacy and Cost Benefit of Low-Dose Granulocyte Colony-Stimulating Factor after Standard Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.

Clinical Trial of Rituximab Synchronized with Granulocyte Colony-Stimulating Factor in Standard CHOP Chemotherapy for Previously Untreated Patients with Follicular or Diffuse Large B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Risk Factor Analysis Of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndromes: A Multicenter Study

Role of Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia in an HTLV-1 Non-Endemic Area of Japan.

Clinical Efficacy and Cost Benefit of Low-Dose Granulocyte Colony-Stimulating Factor after Standard Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.

Clinical Trial of Rituximab Synchronized with Granulocyte Colony-Stimulating Factor in Standard CHOP Chemotherapy for Previously Untreated Patients with Follicular or Diffuse Large B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only